[Evaluation of the effectiveness and tolerance of cicletanine in patients with essential hypertension treated with beta-blockers].

The effectiveness and safety of cicletanine hydrochloride, the first representative of the furopyridine family, were evaluated in a 90-day double-blind study involving 120 patients with moderate essential hypertension poorly controlled after at least one month of treatment with a beta-blocker. After a 30-day pre-inclusion period during which a placebo capsule was given together with a stable dose of the beta-blocker, the patients were randomised to one of three therapeutic groups: group 1 (placebo, n = 40), group 2 (cicletanine 50 mg/day, n = 41), group 3 (cicletanine 100 mg/day, n = 39). All three groups were matched in every respect.

[Evaluation of cicletanine efficiency and tolerance in hypertensive patients treated with beta-blockaders].

Efficacy and tolerance of cicletanine, the first derivative of furopyridines have been studied in a 3 parallel groups double blind study; 120 essential mild hypertensive patients uncontrolled by beta blocking therapy were included. After a period of one month during which a treatment by placebo was added to beta blocking therapy, the patients were randomly allocated into 3 groups: group I (placebo: 40 patients), group II (cicletanine 50 mg/d: 41 patients), group III (cicletanine 100 mg/d: 39 patients). Eight patients were withdrawn in the group I (poor efficacy, n = 5 or unexpected event, n = 3), and one in the group III (unexpected event).

[Dibekacin in the treatment of septicemia].

During an open multicentric trial (17 centers), we have treated 62 septicemia by dibekacin, alone or associated with other antibacterial drugs. Taking into account the degree of severity of these patients, the results are considered satisfactory in 47 patients. 15 failures were noted (including 9 deaths).